Sangamo Therapeutics Inc (SGMO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Sales | 49,412 | 356 | 481 | 2,042 | 9,398 |
| Gross Profit | 49,412 | 356 | 481 | 2,042 | 9,398 |
| Operating Expenses | 38,781 | 37,440 | 52,007 | 64,101 | 115,806 |
| Operating Income | 10,631 | -37,084 | -51,526 | -62,059 | -106,408 |
| Other Income | 129 | 1,030 | 2,535 | 1,492 | 3,515 |
| Pre-tax Income | 10,760 | -36,054 | -48,991 | -60,567 | -102,893 |
| Income Tax | 88 | 74 | 98 | -272 | 1,270 |
| Net Income Continuous | 10,672 | -36,128 | -49,089 | -60,295 | -104,163 |
| Net Income | $10,672 | $-36,128 | $-49,089 | $-60,295 | $-104,163 |
| EPS Basic Total Ops | 0.05 | -0.18 | -0.27 | -0.36 | -0.59 |
| EPS Basic Continuous Ops | 0.05 | -0.18 | -0.27 | -0.36 | -0.59 |
| EPS Diluted Total Ops | 0.04 | -0.18 | -0.27 | -0.35 | -0.59 |
| EPS Diluted Continuous Ops | 0.05 | -0.18 | -0.27 | -0.36 | -0.59 |
| EPS Diluted Before Non-Recurring Items | 0.04 | -0.17 | -0.27 | N/A | N/A |
| EBITDA(a) | $12,758 | $-34,511 | $-49,273 | $-59,348 | $-99,154 |